TITLE

Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients

AUTHOR(S)
Biolo, Gianni; Guarnieri, Gianfranco; Barazzoni, Rocco; Panzetta, Giovanni
PUB. DATE
September 2011
SOURCE
Clinical & Experimental Medicine;Sep2011, Vol. 11 Issue 3, p181
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Insulin resistance and anemia secondary to erythropoietin deficiency characterize patients with end-stage kidney disease. In a cross-sectional analysis, we examined the relationship between erythropoietin-mediated correction of anemia and insulin sensitivity in nondiabetic hemodialysis patients. Insulin sensitivity (euglycemic-hyperinsulinemic clamp) and endogenous glucose production (primed-continuous infusion of [6,6-H]glucose) were determined in two groups of patients with normal hemoglobin ( n:8; mean hemoglobin: 14.0 � 0.3 g/dl) or with mild anemia ( n:10; mean hemoglobin: 12.1 � 0.9 g/dl). The patients with normal hemoglobin were receiving higher ( P < 0.05) erythropoietin doses than those with mild anemia (171 � 73 and 91 � 39 U kg wk, respectively). The two groups were matched for all other potential determinants of insulin resistance. Endogenous glucose production was similar in the two groups of patients in the postabsorptive state and was completely suppressed by insulin infusion. During the hyperinsulinemic clamp, the rate of glucose infusion to maintain euglycemia was significantly lower ( P < 0.01) in the patients with normal hemoglobin levels [166 � 31 mg (m) min] than in those with mild anemia [251 � 49 mg (m) min] and in a group of matched controls [275 � 68 mg (m) min]. In pooled patients, individual values of hemoglobin concentrations inversely correlated with the rates of insulin-mediated glucose infusion, both as absolute values ( r = -0.58; P < 0.05) and as values normalized by steady-state plasma insulin concentration ( r = -0.74; P < 0.001). In conclusion, this exploratory study indicates that complete correction of anemia by erythropoietin treatment in patients with end-stage kidney disease on hemodialysis is associated with impaired insulin sensitivity.
ACCESSION #
63286390

 

Related Articles

  • Adiposity and insulin resistance in nondiabetic hemodialysis patients: effects of high energy supplementation.  // American Journal of Clinical Nutrition;Jul2009, Vol. 90 Issue 1, p64 

    The article presents a study that determines the effect of high energy supplementation on the diposity and insulin resistance of nondiabetic hemodialysis patients. It offers details of the method of the study that investigates the association between body fat mass and insulin resistance in 106...

  • Impact of C-reactive protein on absolute reticulocyte count in haemodialysis patients: the role of iron status. Mitsopoulos, Efstathios; Tsiatsiou, Maria; Zanos, Stavros; Katodritou, Eirini; Visvardis, Georgios; Papadopoulou, Dorothea; Passadakis, Ploumis; Vargemezis, Vassilis; Tsakiris, Dimitrios // Nephrology Dialysis Transplantation;Mar2011, Vol. 26 Issue 3, p992 

    Background. Τhe exact mechanisms by which the effects of inflammation on erythropoiesis occur are still to be determined. We aimed to examine the relation between C-reactive protein (CRP) and erythropoiesis as quantified by the absolute reticulocyte count (RTC) and the possible effect of iron...

  • Association between Serum Magnesium and Erythropoietin Responsiveness in Hemodialysis Patients: A Cross-Sectional Study. Yu, Ling; Song, Jinghong; Lu, Xiangxue; Zu, Yuan; Li, Han; Wang, Shixiang // Kidney & Blood Pressure Research;2019, Vol. 44 Issue 3, p354 

    Background/Aims: As shown in the China Health and Nutrition Survey, serum magnesium is associated with anemia. However, the roles of magnesium in anemia and erythropoietin (EPO) responsiveness remain unclear in maintenance hemodialysis (MHD) patients. This study aims to investigate the level of...

  • Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Aapro, M.; Ludwig, H.; Bokemeyer, C.; MacDonald, K.; Soubeyran, P.; Turner, M.; Albrecht, T.; Abraham, I. // Annals of Oncology;Oct2009, Vol. 20 Issue 10, p1714 

    Background: In anemic cancer patients treated with erythropoiesis-stimulating agent (ESA), (i) to examine the proportion of variance in hemoglobin (Hb) outcomes attributable to patients versus center, country, and region and (ii) to develop predictive models of treatment response.

  • Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Singh, Ajay K.; Milford, Edgar; Fishbane, Steven; Keithi-Reddy, Sai Ram // Kidney International;Sep2008, Vol. 74 Issue 5, p679 

    The article presents a discussion on management of anemia in dialysis patients. It mentions that anemia is present in most of patients on dialysis and presents a combination of erythropoietin deficiency and iron deficiency, as well as bone marrow resistance to erythropoietin. The management of...

  • Intravenous iron administration strategies and anemia management in hemodialysis patients. Michels, Wieneke M.; Jaar, Bernard G.; Ephraim, Patti L.; Yang Liu; Miskulin, Dana C.; Tangri, Navdeep; Crews, Deidra C.; Scialla, Julia J.; Shafi, Tariq; Sozio, Stephen M.; Bandeen-Roche, Karen; Cook, Courtney J.; Meyer, Klemens B.; Boulware, L. Ebony // Nephrology Dialysis Transplantation;Jan2017, Vol. 32 Issue 1, p173 

    Background. The effect of maintenance intravenous (IV) iron administration on subsequent achievement of anemia management goals and mortality among patients recently initiating hemodialysis is unclear. Methods. We performed an observational cohort study, in adult incident dialysis patients...

  • Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients. Satirapoj, Bancha; Dispan, Rattanawan; Supasyndh, Ouppatham // International Journal of Nephrology & Renovascular Disease;Sep2017, Vol. 10, p275 

    Background: Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EPO). This study investigated the therapeutic equivalence between lyophilized powder and standard liquid EPO alfa by subcutaneous (SC) administration in hemoglobin...

  • Current state and perspectives on erythropoietin production. Lee, Jae; Ha, Tae; Lee, Seung; Lee, Gyun // Applied Microbiology & Biotechnology;Sep2012, Vol. 95 Issue 6, p1405 

    Erythropoietin is a major regulator of erythropoiesis which maintains the body's red blood cell mass and tissue oxygenation at an optimum level. Recombinant human erythropoietin (rhEPO), which is a widely used therapeutic agent for the treatment of anemia and which represents one of the largest...

  • Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia. Duman, Neval; Uyanik, Abdullah; Unsal, Abdulkadir; Sezer, Siren; Camsari, Taner; Cirit, Mustafa; Yilmaz, Mehmet Emin; Altun, Bülent; Duranay, Murat; Yildiz, Alaattin; Sahin, Idris; Dogukan, Ayhan; Ustundag, Sedat; Karayaylali, Ibrahim; Kahveci, Arzu; Sindel, Sukru; Kiykim, Ahmet Alper; Yenicerioglu, Yavuz; Akbas, Ertugrul; Ozdener, Fatih // Clinical Kidney Journal;Oct2014, Vol. 7 Issue 5, p464 

    Background This study was conducted to evaluate the efficacy and safety of once-monthly continuous erythropoietin receptor activator (CERA) for maintenance of stable haemoglobin (Hb) levels in adult chronic renal anaemia patients on dialysis according to local clinical judgment in Turkey....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics